Ultragenyx Q3 revenue rises, net loss narrows
RARE•Ultragenyx reported third-quarter revenue of $173 million, up from $160 million a year earlier, and a net loss of $118 million, down from $180 million. It reaffirmed 2026 revenue guidance of $730 million to $760 million and expects full-year GAAP profitability in 2027.
1. Quarterly results
Ultragenyx's third-quarter revenue rose to $173 million from $160 million a year earlier, while its net loss narrowed to $118 million from $180 million. The company reported a loss per share of $1.16 and operating expenses of $283 million.
2. Outlook and demand
The company reaffirmed its 2026 total revenue guidance of $730 million to $760 million and Crysvita revenue guidance of $500 million to $520 million. It expects to achieve full-year GAAP profitability in 2027. Ultragenyx said launches of newly approved gene therapies GENGLYCOS and FAYUVI are progressing well with growing demand, while EVKEEZA revenue benefited from demand following new country launches and early access.
